ALSO NOTED: Promacta gets priority review; GTx drug hits endpoint; Alexza touts IIa data; and much more...

> Glaxo's Promacta, a bleeding disorder drug, will be given a priority review by the FDA. Release [1]

> GTx announced that an 80 mg dose of toremifene citrate experienced reduced rates of hot flashes in prostate cancer patients on ADT therapy, hitting a secondary endpoint in a late-stage trial. Report [2]

> Alexza Pharmaceuticals announced that its Phase IIa trial for its migraine drug AZ-104 hits its primary endpoint of two-hour pain relief after two doses compared to placebo. Report [3]

> Denmark's Neurosearch reported positive data for its obesity drug. "Neurosearch considers the TIPO-2 results highly supportive for the continued development of Tesofensine both in terms of superior efficacy and safety." Release [4]

> Valeant Pharmaceuticals has sold its Asian operations to Invida Pharmaceutical for $37.8 million. Release [5]

> AEterna Zentaris and Paladin Labs have inked a sales deal on all rights related to miltefosine for Cdn$9.125 million in cash. Release [6]

> A hedge fund has cut its holdings in CV Therapeutics to 2.1 percent. Report [7]

> Put your cards on the table, ladies and gentlemen. A U.K. minister is calling on drug companies to hand over all their data on antidepressants to the National Institute for Health and Clinical Excellence. Report [8]

> Want to know what happens inside a pharma company during a recall crisis? Check out Sunday's Chicago Tribune, which details the behind-the-scenes scramble at Baxter. Report [9]

> Celebs may help sell magazines but do they really help market drugs? In the wake of Robert Jarvik's public downfall from Pfizer's pitchman-pedestal, advertising experts are wondering. Report [10]

And Finally... Narcoleptics experience a high rate of eating disorders, with binge eating and food craving at the top of the list. Release [11]